Eval Gal-Oz Clinical is categorized under Business Services (Unclassified) in Palo Alto, CA and active since 2011.
Eval Gal-Oz Clinical was established in 2011, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Business Services (Unclassified) business, which does work in the B2B market, and is classified as a Business Services (Unclassified), under code number 561499 by the NAICS.
If you are seeking more information, feel free to contact Eval Gal Oz, President at the company’s single location by writing to 378 Cambridge Avenue # B, Palo Alto, California CA 94306 or by phoning (650) 714-0400. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Eval Gal-Oz Clinical |
| Contact Person: | Eval Gal Oz, President |
| Address: | 378 Cambridge Avenue # B, Palo Alto, California 94306 |
| Phone Number: | (650) 714-0400 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2011 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Business Services (Unclassified) |
| SIC Code: | 7389 |
| NAICS Code: | 561499 |
| Share This Business: |
Eval Gal-Oz Clinical was started in 2011 to provide professional Business Services (Unclassified) under the SIC code 7389 and NAICS code 561499. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Eval Gal Oz, President for inquiries that concern Eval Gal-Oz Clinical by calling the company number (650) 714-0400, as your correspondence is most welcome. Additionally, the physical location of the single location of Eval Gal-Oz Clinical can be found at the coordinates 37.42762,-122.14518 as well as the street address 378 Cambridge Avenue # B in Palo Alto, California 94306.
For its online presence, you may visit Eval Gal-Oz Clinical’s website at and engage with its social media outlets through on Twitter and on Facebook.